This supplemental administrative grant will allow a three-person Company team to participate in the Information Corps (iCorps) program to accelerate commercialization of the Company?s predicate STTR Phase I grant technology, which is the development of a pharmaceutical treatment for traumatic brain injury. I-Corps is an intense eight-week entrepreneurial emersion course and requires the team to create a business canvas through conducting 100+ customer interviews. The team consists of the Company?s Chief Executive Officer, Medical Officer and the Principal Investigator of the predicate grant.
Currently, there is no pharmaceutical treatment for traumatic brain injury (TBI) and as such there is an urgent need for an effective TBI therapeutic to reach the market. This administrative supplement will accelerate commercialization of the promising TBI therapeutic being developed by American Life Science Pharmaceuticals in its predicate scientific STTR Phase I grant by providing Company executives with the entrepreneurial acumen needed to get the treatment to TBI patients.